CL2021001225A1 - Ácidos nucleicos para inhibir la expresión de lpa en una célula - Google Patents
Ácidos nucleicos para inhibir la expresión de lpa en una célulaInfo
- Publication number
- CL2021001225A1 CL2021001225A1 CL2021001225A CL2021001225A CL2021001225A1 CL 2021001225 A1 CL2021001225 A1 CL 2021001225A1 CL 2021001225 A CL2021001225 A CL 2021001225A CL 2021001225 A CL2021001225 A CL 2021001225A CL 2021001225 A1 CL2021001225 A1 CL 2021001225A1
- Authority
- CL
- Chile
- Prior art keywords
- expression
- cell
- nucleic acids
- lpa expression
- inhibiting lpa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2018/081106 WO2019092283A1 (en) | 2017-11-13 | 2018-11-13 | Nucleic acids for inhibiting expression of lpa in a cell |
| EP19174466 | 2019-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001225A1 true CL2021001225A1 (es) | 2021-12-24 |
Family
ID=66554180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001225A CL2021001225A1 (es) | 2018-11-13 | 2021-05-10 | Ácidos nucleicos para inhibir la expresión de lpa en una célula |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20220002722A1 (https=) |
| EP (2) | EP3880818B1 (https=) |
| JP (1) | JP7245328B2 (https=) |
| KR (1) | KR102553386B1 (https=) |
| CN (2) | CN113227372A (https=) |
| AU (1) | AU2019380628B2 (https=) |
| BR (1) | BR112021009213A2 (https=) |
| CA (1) | CA3119239C (https=) |
| CL (1) | CL2021001225A1 (https=) |
| CO (1) | CO2021007372A2 (https=) |
| CR (1) | CR20210301A (https=) |
| DK (1) | DK3880818T3 (https=) |
| EA (1) | EA202190895A1 (https=) |
| ES (1) | ES2932295T3 (https=) |
| FI (1) | FI3880818T3 (https=) |
| HR (1) | HRP20221358T1 (https=) |
| HU (1) | HUE060703T2 (https=) |
| IL (1) | IL283159B1 (https=) |
| LT (1) | LT3880818T (https=) |
| MA (1) | MA58208B1 (https=) |
| MX (1) | MX2021005590A (https=) |
| PE (1) | PE20211282A1 (https=) |
| PH (1) | PH12021550801B1 (https=) |
| PL (1) | PL3880818T3 (https=) |
| PT (1) | PT3880818T (https=) |
| RS (1) | RS63778B1 (https=) |
| SA (1) | SA521421963B1 (https=) |
| SG (1) | SG11202103882QA (https=) |
| SI (1) | SI3880818T1 (https=) |
| SM (1) | SMT202300050T1 (https=) |
| WO (1) | WO2020099476A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7155239B2 (ja) * | 2017-04-05 | 2022-10-18 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| MX2020004897A (es) | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| BR112021009213A2 (pt) | 2018-11-13 | 2021-08-10 | Silence Therapeutics Gmbh | ácidos nucleicos para inibição da expressão de lpa em uma célula |
| US20240035029A1 (en) | 2020-10-16 | 2024-02-01 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
| WO2023041508A2 (en) * | 2021-09-14 | 2023-03-23 | Argonaute RNA Limited | Treatment of cardiovascular disease |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| IL314872A (en) | 2022-02-09 | 2024-10-01 | Silence Therapeutics Gmbh | Therapeutic inhibition of LPA expression |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| WO2024013334A1 (en) * | 2022-07-15 | 2024-01-18 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of agt in a cell |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| IL321855A (en) * | 2023-01-13 | 2025-08-01 | Lilly Co Eli | Pharmaceutical preparations containing therapeutic oligonucleotides and dosage regimens using the same |
| CN119585432B (zh) * | 2023-08-22 | 2025-08-12 | 成都先衍生物技术有限公司 | 一种靶向AGT基因表达的siRNA及其缀合物和用途 |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| WO2026046152A1 (zh) * | 2024-08-26 | 2026-03-05 | 倍臻生物技术（苏州）有限公司 | 修饰的双链核糖核酸及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| US20060160759A1 (en) | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
| CN101278059A (zh) * | 2005-07-28 | 2008-10-01 | 肿瘤疗法科学股份有限公司 | 诊断和治疗肾细胞癌的方法 |
| US20110110886A1 (en) | 2008-06-13 | 2011-05-12 | Yale University | Small molecule inhibitors of autotaxin and methods of use |
| EP2490699A1 (en) * | 2009-10-20 | 2012-08-29 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| EP3564374A1 (en) * | 2013-06-21 | 2019-11-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| US20160272970A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| EP3228326A1 (en) * | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| JP7155239B2 (ja) | 2017-04-05 | 2022-10-18 | サイレンス・セラピューティクス・ゲーエムベーハー | 産物及び組成物 |
| CA3118327A1 (en) * | 2017-11-13 | 2019-05-16 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of aldh2 in a cell |
| MX2020004897A (es) * | 2017-11-13 | 2020-10-05 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de lpa en una celula. |
| BR112021009213A2 (pt) | 2018-11-13 | 2021-08-10 | Silence Therapeutics Gmbh | ácidos nucleicos para inibição da expressão de lpa em uma célula |
-
2019
- 2019-11-13 BR BR112021009213-7A patent/BR112021009213A2/pt active IP Right Grant
- 2019-11-13 CA CA3119239A patent/CA3119239C/en active Active
- 2019-11-13 WO PCT/EP2019/081158 patent/WO2020099476A1/en not_active Ceased
- 2019-11-13 RS RS20221119A patent/RS63778B1/sr unknown
- 2019-11-13 HR HRP20221358TT patent/HRP20221358T1/hr unknown
- 2019-11-13 AU AU2019380628A patent/AU2019380628B2/en active Active
- 2019-11-13 MA MA58208A patent/MA58208B1/fr unknown
- 2019-11-13 JP JP2021525771A patent/JP7245328B2/ja active Active
- 2019-11-13 SG SG11202103882QA patent/SG11202103882QA/en unknown
- 2019-11-13 US US17/293,303 patent/US20220002722A1/en not_active Abandoned
- 2019-11-13 CN CN201980074785.8A patent/CN113227372A/zh active Pending
- 2019-11-13 EP EP19801033.2A patent/EP3880818B1/en active Active
- 2019-11-13 PH PH1/2021/550801A patent/PH12021550801B1/en unknown
- 2019-11-13 PT PT198010332T patent/PT3880818T/pt unknown
- 2019-11-13 EA EA202190895A patent/EA202190895A1/ru unknown
- 2019-11-13 MX MX2021005590A patent/MX2021005590A/es unknown
- 2019-11-13 ES ES19801033T patent/ES2932295T3/es active Active
- 2019-11-13 PL PL19801033.2T patent/PL3880818T3/pl unknown
- 2019-11-13 EP EP22197500.6A patent/EP4219712A3/en not_active Withdrawn
- 2019-11-13 SI SI201930387T patent/SI3880818T1/sl unknown
- 2019-11-13 PE PE2021000650A patent/PE20211282A1/es unknown
- 2019-11-13 SM SM20230050T patent/SMT202300050T1/it unknown
- 2019-11-13 KR KR1020217017471A patent/KR102553386B1/ko active Active
- 2019-11-13 FI FIEP19801033.2T patent/FI3880818T3/fi active
- 2019-11-13 CR CR20210301A patent/CR20210301A/es unknown
- 2019-11-13 CN CN202510076171.0A patent/CN119842706A/zh active Pending
- 2019-11-13 HU HUE19801033A patent/HUE060703T2/hu unknown
- 2019-11-13 DK DK19801033.2T patent/DK3880818T3/da active
- 2019-11-13 LT LTEPPCT/EP2019/081158T patent/LT3880818T/lt unknown
-
2021
- 2021-05-06 SA SA521421963A patent/SA521421963B1/ar unknown
- 2021-05-10 CL CL2021001225A patent/CL2021001225A1/es unknown
- 2021-05-12 IL IL283159A patent/IL283159B1/en unknown
- 2021-06-04 CO CONC2021/0007372A patent/CO2021007372A2/es unknown
- 2021-12-22 US US17/559,479 patent/US11499153B2/en active Active
-
2025
- 2025-07-08 US US19/263,110 patent/US20260078372A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001225A1 (es) | Ácidos nucleicos para inhibir la expresión de lpa en una célula | |
| MX2020004897A (es) | Acidos nucleicos para inhibir la expresion de lpa en una celula. | |
| CO2017004728A2 (es) | Composiciones y métodos para inhibir la expresión del gen hao1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa) | |
| CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
| BR112016029041A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| CL2020000422A1 (es) | Composiciones de glp-1 y sus usos. | |
| PE20201287A1 (es) | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso | |
| MX393975B (es) | Plantas que muestran una reducción en el cambio de coloración en la superficie inducido por heridas. | |
| MX2017016289A (es) | Mutaciones de la enzima crispr que reducen los efectos fuera del blanco. | |
| MX2016010071A (es) | Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos. | |
| MX2019005898A (es) | Composiciones de arni de serpina 1 y sus métodos de uso. | |
| MX376835B (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| CO2021002691A2 (es) | Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1) | |
| MX389847B (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| CO2022009787A2 (es) | Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos | |
| UY34773A (es) | Ácidos indanoiloxidihidrobenzofuranilacéticos como moduladores de la actividad de gpr40, composiciones que los contienen y sus usos | |
| MX2017011500A (es) | Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX387275B (es) | Neoepítopos virales y sus usos | |
| EP3483271A3 (en) | Products and compositions | |
| MX386098B (es) | Analogos metabolicamente robustos de cyp-eicosanoides para el tratamiento de enfermedades cardiacas. | |
| PH12017501692A1 (en) | Solid forms of menaquinols | |
| UY37294A (es) | Promotor vegetal y 3# utr para la expresión de transgenes | |
| BR112017001121A2 (pt) | adjuvantes | |
| UY37219A (es) | Promotor vegetal y 3’utr para la expresión de transgenes | |
| AR103676A1 (es) | COMPOSICIONES DE ARNi QUE CONTIENEN UN DOMINIO FOSFOLIPASA TIPO PATATINA 3 (PNPLA3) Y SUS MÉTODOS DE USO |